Neuromodulator Comparison
Botox vs Dysport
vs Xeomin
OnabotulinumtoxinA vs AbobotulinumtoxinA vs IncobotulinumtoxinA
Written by the Vera Beauty Editorial Team · Last updated March 2026
All three are FDA-approved botulinum toxin type A neuromodulators for glabellar lines. They share the same mechanism but differ in unit potency, onset speed, diffusion pattern, and formulation. Botox is the most established with the broadest approvals; Dysport spreads faster and may suit larger treatment areas; Xeomin is the only one free of complexing proteins.
|
Botox |
Dysport |
Xeomin |
| Neuromodulator injection |
Neuromodulator injection |
Neuromodulator injection |
| OnabotulinumtoxinA |
AbobotulinumtoxinA |
IncobotulinumtoxinA |
| Human serum albumin |
Lactose + human albumin |
None (complexing-protein-free) |
| 2002 (glabellar lines) |
2009 (glabellar lines) |
2011 (glabellar lines) |
| 3–7 days |
2–5 days (faster) |
3–7 days |
| 3–4 months |
3–4 months (slightly shorter in some studies) |
3–4 months |
| ~$300–$600 |
~$300–$600 (different unit count) |
~$300–$600 |
| Mild |
Mild |
Mild |
| None |
None |
None |
| Glabellar, forehead, crow's feet |
Glabellar lines |
Glabellar lines |
| First-timers, multi-area treatment |
Patients wanting faster onset |
Patients concerned about immunoresistance |
Botox remains the default for first-timers and multi-area treatment — it has the longest track record and the most FDA approvals. Dysport suits patients who prefer a faster onset and don't mind a slightly wider diffusion pattern. Xeomin earns its place for patients concerned about immunoresistance or who prefer a protein-free formulation. All three deliver comparable results; the differences are clinically meaningful only in specific situations.
How does Botox (onabotulinumtoxinA) work?
Botox (onabotulinumtoxinA) is a purified form of botulinum toxin type A that blocks neuromuscular signaling at the injection site. After the toxin is taken up by the nerve terminal via receptor-mediated endocytosis, it cleaves SNAP-25 — a synaptosomal-associated protein required for acetylcholine vesicle fusion[6]. Without SNAP-25 intact, the nerve terminal cannot release acetylcholine and the target muscle cannot contract.
The result is a temporary, localized reduction in muscle movement in the treated area. Dynamic wrinkles — those caused by repeated muscle contractions like frowning, squinting, or raising the brows — soften as the muscle remains at rest. The effect is fully reversible: as nerve terminals regenerate and new SNAP-25 is synthesized, muscle function gradually returns over 3–4 months.
Botox received its first FDA cosmetic approval in 2002 for moderate to severe glabellar lines, with subsequent approvals for forehead lines (2017) and crow's feet (2013) — giving it the broadest label of the three products. It remains the market-leading neuromodulator globally by volume.
▸
In the pivotal phase 3 studies supporting FDA approval, onabotulinumtoxinA achieved statistically significant reduction in glabellar line severity at Day 30 versus placebo, with a well-characterized safety profile across thousands of subjects[1].
How does Dysport (abobotulinumtoxinA) differ from Botox?
Dysport (abobotulinumtoxinA) uses the same mechanism as Botox — SNAP-25 cleavage at the neuromuscular junction — but differs in its protein complex, unit potency, and pharmacokinetic profile. AbobotulinumtoxinA is formulated with lactose and human serum albumin rather than albumin alone. Because the toxin is complexed with different accessory proteins, dosing is not equivalent: a typical Botox glabellar dose of 20 units corresponds roughly to 50 Dysport units in the same indication.
The most clinically discussed difference is onset speed. Multiple phase 3 studies of abobotulinumtoxinA have documented faster time to response compared to onabotulinumtoxinA. A subset analysis of phase 3 Dysport trials found that the median time to onset was 2–4 days, with over 13% of patients showing measurable response within the first 24 hours[3]. This makes Dysport a practical consideration for patients who need results quickly before an event.
A secondary consideration is diffusion. AbobotulinumtoxinA is widely discussed as having a wider diffusion radius than Botox, which can be advantageous for large, flat muscles like the forehead but requires greater precision near the upper eyelid levator muscle to avoid ptosis. The clinical significance of diffusion differences remains technique-dependent and provider-specific.
▸
A pooled efficacy analysis of four phase 3 Dysport trials demonstrated response rates comparable to other neuromodulators, with the fastest median onset reported among currently approved botulinum toxin formulations — 2–4 days in phase 3 data[2].
What makes Xeomin (incobotulinumtoxinA) different?
Xeomin (incobotulinumtoxinA) is the only FDA-approved neuromodulator formulated without complexing proteins. Where Botox and Dysport include accessory proteins around the 150 kDa neurotoxin core, Xeomin contains only the active neurotoxin itself — often described as a "naked" toxin. This is achieved through an additional purification step in manufacturing.
The practical implication is twofold. First, Xeomin does not require refrigeration prior to reconstitution in the same manner as other neuromodulators — the absence of complexing proteins confers improved room-temperature stability. Second, the protein-free formulation is theorized to reduce the immunogenic load with repeated injections, potentially lowering the risk of neutralizing antibody formation over long-term treatment courses.
A Phase III study of incobotulinumtoxinA for glabellar frown lines showed strong efficacy at 20 units, with approximately 98% of subjects responding by day 28 at maximum frown and 80% maintaining improvement at day 84[4]. Notably, no patients in that study developed neutralizing antibodies, supporting the theoretical immunogenic advantage of the protein-free formulation.
Xeomin's onset time and duration are broadly comparable to Botox — approximately 3–7 days to onset and 3–4 months of effect. The 1:1 unit equivalence with Botox in the glabellar indication simplifies switching for experienced patients and providers.
How do the onset times compare across all three neuromodulators?
Onset speed is one of the most practically meaningful differences among the three products for patients with time-sensitive treatment goals. The clinical data is fairly consistent across multiple studies:
- Dysport (abobotulinumtoxinA): Fastest onset. Phase 3 data shows median time to response of 2–4 days, with a meaningful percentage of patients showing initial effect within 24 hours[3].
- Botox (onabotulinumtoxinA): Onset typically 3–7 days, with full effect at approximately 2 weeks. Most patients and providers use a 2-week follow-up window before assessing whether touch-up is needed[1].
- Xeomin (incobotulinumtoxinA): Onset broadly comparable to Botox — 3–7 days — based on phase 3 trial data[4].
For patients planning treatment before a specific event (wedding, major presentation, photoshoot), the 1–3 day advantage of Dysport can be worth factoring into timing. For most routine maintenance appointments, the difference is not clinically significant.
Duration across all three products is broadly similar in the glabellar indication — approximately 3–4 months in most clinical studies. Some real-world data suggests Dysport may wear off slightly sooner in a subset of patients, though controlled head-to-head studies show comparable median durations. The comparison is complicated by non-equivalent unit dosing across products.
Which neuromodulator is right for you: Botox, Dysport, or Xeomin?
All three products deliver effective treatment for glabellar lines and have established safety records. The right choice depends on your treatment history, goals, and the areas being treated.
| If you… |
Consider |
Reason |
| Are new to neuromodulators |
Botox |
Longest track record, most FDA approvals, most provider experience. A good first baseline. |
| Want the fastest onset before an event |
Dysport |
Median 2–4 day onset vs. 3–7 days for Botox and Xeomin per phase 3 data. |
| Are concerned about immunoresistance after years of Botox |
Xeomin |
Protein-free formulation removes complexing proteins that may contribute to neutralizing antibody formation. |
| Want to treat forehead lines or crow's feet |
Botox |
Only Botox holds FDA approvals for forehead lines and crow's feet among the three. |
| Are treating a large area like the forehead |
Dysport |
Wider diffusion pattern may cover larger muscle groups more evenly — discuss technique with your provider. |
| Had Botox results diminish over time |
Xeomin or Dysport |
Switching formulations — particularly to Xeomin's protein-free version — is a reasonable clinical trial for suspected resistance. |
The clinical literature confirms that all three products achieve comparable levels of glabellar line improvement when dosed appropriately[5]. Provider experience with each formulation, local availability, and institutional preference all play a role in which product is offered. Discussing specific goals — onset timing, treatment area, and history with other neuromodulators — with your provider is the most reliable way to choose.
What questions should you ask your provider before choosing a neuromodulator?
Bring these to your consultation to make a more confident decision:
- How many units do you use for each product in this area, and what is the all-in session cost? Units are not equivalent across products — a Dysport session uses roughly 2.5× more units than a Botox session for the same effect.
- Based on my muscle anatomy and the area I'm treating, which product do you prefer and why? Providers who use all three regularly will have real clinical observations about which works better in specific anatomical contexts.
- Have you seen any diffusion-related complications with Dysport in the areas I'm treating? The forehead and areas near the eyelid levator have different risk profiles for product spread.
- I've had neuromodulators for X years — do you think Xeomin is worth trying for potential immunoresistance? Long-term users who report diminishing results should have this conversation explicitly.
- What is your touch-up policy, and how long do you want me to wait before assessing results? Two weeks is the standard assessment window for neuromodulators; confirming this prevents premature retreatment.